Sodium –glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser and M. Arad Tags: Original investigation Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Disease | Heart Failure | Sodium